Net sales reached $154.2 million, a 4.1% increase compared to $148.1 million in Q1 2025. Net income rose to $17.5 million, compared to $17.2 million in the prior year period. Medical market sales grew 5.9%, while non-medical market sales declined by 15%. Gross margin improved slightly to 28.8% from 28.5% in Q1 2025. Diluted earnings per share were $2.24, up from $2.21 in Q1 2025.